GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Capex-to-Operating-Cash-Flow

PixarBio (PixarBio) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2016)


View and export this data going back to 2016. Start your Free Trial

What is PixarBio Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

PixarBio's Capital Expenditure for the three months ended in Sep. 2016 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2016 was $-0.06 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


PixarBio Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for PixarBio's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Capex-to-Operating-Cash-Flow Chart

PixarBio Annual Data
Trend Dec14 Dec15
Capex-to-Operating-Cash-Flow
- -

PixarBio Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PixarBio's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, PixarBio's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PixarBio's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PixarBio's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where PixarBio's Capex-to-Operating-Cash-Flow falls into.



PixarBio Capex-to-Operating-Cash-Flow Calculation

PixarBio's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2015 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.111
=N/A

PixarBio's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2016 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.056
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PixarBio  (GREY:PXRB) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


PixarBio Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of PixarBio's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


PixarBio (PixarBio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155
PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.

PixarBio (PixarBio) Headlines